ClinicalTrials.gg
Active, not recruitingNCT07184632Updated May 7, 2026

A Research Study on How Well Different Doses of the Medicine NNC0662-0419 Help People Living With Overweight or Obesity

A Phase 2 interventional study of NNC0662-0419 and Placebo in Overweight and Obesity, sponsored by Novo Nordisk A/S. Active, not recruiting at 2 sites in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-05-07.

Primary conditionObesityRegistry: OverweightReclassifiedWhy we changed it
Registry
Overweight — the first condition term the registry derived for this study.
ClinicalTrials.gg
Obesity
Why
  1. The study's listed conditions name Obesity, a narrower term within Overweight.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Novo Nordisk A/S · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
224
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 207 studies in Obesity by Novo Nordisk A/S — 48 open to participants now, 66 under way, 26 of them phase 3. Obesity · Novo Nordisk A/S.

Enrollment
67th of 166
224 · median 138
Started
2025
with 21 others
Phase 2
13 of 207
1 open now
Primary completion
2026-12
later than 6 of 65 live
Registered
154th of 207
by date

Among the 207 studies in Obesity by Novo Nordisk A/S, this one is the 67th largest by enrollment of the 166 interventional ones that give a count, is one of 22 that started in 2025, is one of 13 in phase 2, reaches primary completion later than 6 of the 65 other live ones, and was the 154th registered.

Obesity

11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.

Browse Obesity studies →

Open to participants now

48 of the 207 studies in Obesity by Novo Nordisk A/S are open now, in 12 countries. Recruiting first, the newest first:

43 more — sign in →

By country, each count listing its studies:

All 48 open studies →

Who these studies take

Of the 1,342 Obesity studies recruiting now, 377 (28%) set no upper age limit and 861 (64%) stop at 75 or younger; 168 take children under 18; 489 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 207 studies in Obesity by Novo Nordisk A/S, or all of them as a file.
02

Study summary

This study tests how well different doses of the medicine NNC0662-0419 help people living with overweight or obesity. The purpose of the study is to find out if NNC0662-0419 is safe and effective for treating people living with overweight or obesity. There are 2 study treatments in this study, participants will get either NNC0662-0419, the treatment being tested or placebo, a treatment that has no active medicine in it. NNC0662-0419 is a new medicine which cannot be pre-scribed by doctors but has previously been tested in humans.

03

Conditions studied

  • Overweight
  • Obesity

Browse trials for

04

In context

Obesity Reclassified

11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.

This study's enrollment of 224 is above the median of 67 across 9,023 interventional studies indexed under Obesity.

Browse Obesity studies →

Lead sponsor

Novo Nordisk A/S is the lead sponsor of 1,408 studies on the registry; 105 are open to participants now.

Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.

Compared within Obesity, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Overweight. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female (sex at birth).
  • Age at the time of signing the :

    • For Part A:18-55 years (both inclusive)
    • For Part B and Part C: 18-65 years (both inclusive)
  • (BMI) at screening (overweight should be due to excess adipose tissue, as judged by the investigator):

    • For Part A: 27.0-39.9 kilogram per square meter(kg/m\^2) (both inclusive)
    • For Part B and Part C:

      1. Greater than or equal to (≥) 27.0 kg/m\^2 with the presence of at least one weight-related comorbidity (e.g. hypertension, dyslipidaemia, obstructive sleep apnoea or CV disease), or
      2. Greater than or equal to (≥) 30.0 kg/m\^2
  • Considered eligible based on the medical history, physical examination, and the results of vital signs, and clinical laboratory tests performed during the screening visit, as-judged by the investigator.
  • Willingness to obtain a high weight loss (greater than [>] 25 percent [%]).

Exclusion criteria

Exclusion criteria:

  • Known or suspected to study intervention(s) or related products.
  • Treatment with any compound containing Glucagon-Like Peptide 1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP) or amylin receptor agonism within 90 days before screening.
  • Any condition, unwillingness or inability, which in the investigator's opinion might jeopardise the participant's safety or compliance with the protocol.
  • 2nd or 3rd degree atrioventricular-block, prolongation of the QRS complex over 120 millisecond (ms), or of the interval by Fridericia (QTcF) calculation over 450 ms (females) or 430 ms (males), or any other abnormal results as judged by the investigator, at screening.
  • Glycosylated () greater than or equal to (≥) 6.5% (48 millimoles per mole [mmol/mol]) at screening.
  • History of type 1 or type 2 diabetes mellitus.
  • Calcitonin greater than or equal to (≥) 50 nanogram per litre (ng/L) at screening.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

06

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
224 participants (actual)

Study arms

  • Experimental
    NNC0662-0419

    Participants will be randomized to receive NNC0662-0419 subcutaneously (s.c.). The study will be conducted in 3 parts. Part A: Multiple ascending dose (MAD), Part B: Dose range finding (DFR) and Part C (2-week escalation).

    Drug: NNC0662-0419

  • Placebo comparator
    Placebo

    Participant will be randomized to receive placebo in: The study will be conducted in 3 parts. Part A: Multiple ascending dose (MAD), Part B: Dose range finding (DFR) and Part C (2-week escalation).

    Drug: Placebo

Interventions

  • NNC0662-0419 will be administered subcutaneously.

  • DrugPlacebo

    Placebo matched to NNC0662-0419 will be administered subcutaneously.

07

What researchers measure

Primary outcomes

  1. Part A: Number of treatment-emergent adverse events (TEAE)

    Measured as number of events.

    Time frame: From baseline (week 0) to end of study (up to week 44)

  2. Part B: Relative change in body weight

    Measured as percentage (%).

    Time frame: From baseline (week 0) to end of treatment (week 36)

  3. Part C: Occurrence of premature treatment discontinuation (Yes/No)

    Measured as count of participants.

    Time frame: At end of treatment (week 24)

Secondary outcomes

  1. Part A: Relative change in body weight

    Measured as percentage (%).

    Time frame: From baseline (week 0) to end of treatment (up to week 40)

  2. Part A: Change in body weight

    Measured in kilograms (kg).

    Time frame: From baseline (week 0) to end of treatment (up to week 40)

  3. Part A: AUC; the area under the NNC0662-0419 plasma concentration-time curve

    Measured in hours\*nanomole per litre (h\*nmol/L).

    Time frame: From pre-dose on day 1 to completion of the end of study visit (up to week 44)

  4. Part A: Cmax; the maximum plasma concentration of NNC0662-0419

    Measured in nanomole per litre (nmol/L).

    Time frame: From pre-dose on day 1 to completion of the end of study visit (up to week 44)

  5. Part B: Change in body weight

    Measured in kg.

    Time frame: From baseline (week 0) to end of treatment (week 36)

  6. Part B: Body weight reduction greater than or equal to (≥) 5% (Yes/No)

    Measured as count of participants.

    Time frame: From baseline (week 0) to end of treatment (week 36)

  7. Part B: Body weight reduction ≥ 10% (Yes/No)

    Measured as count of participants.

    Time frame: From baseline (week 0) to end of treatment (week 36)

  8. Part B: Body weight reduction ≥ 15% (Yes/No)

    Measured as count of participants.

    Time frame: From baseline (week 0) to end of treatment (week 36)

  9. Part B: Body weight reduction ≥ 20% (Yes/No)

    Measured as count of participants.

    Time frame: From baseline (week 0) to end of treatment (week 36)

  10. Part B: Body weight reduction ≥ 25% (Yes/No)

    Measured as count of participants.

    Time frame: From baseline (week 0) to end of treatment (week 36)

  11. Part B: Number of treatment emergent adverse events (TEAE)

    Measured as number of events.

    Time frame: From baseline (week 0) to end of study (week 39)

  12. Part C: Number of treatment emergent adverse events (TEAE)

    Measured as number of events.

    Time frame: From baseline (week 0) to end of study (week 27)

08

Study locations

2 sites
09

References and documents

Individual participant data

Plan to share: Yes — According to the Novo Nordisk disclosure commitment on novonordisk-trials.com.

Data sharing details ↗ · novonordisk-trials.com

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2025 (actual). Primary completion is estimated for Dec 2026, 14 months after the start.

Of 176 industry-sponsored phase 2 interventional studies under Obesity, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 18. This study's planned 14 months is above that.

Counting every sponsor, half of 307 studies reached it within 16 months; a quarter within 10 and three quarters within 35.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 18, 2025
First posted
Sep 22, 2025
StartActual
Oct 1, 2025
Primary completionEst.
Dec 14, 2026
CompletionEst.
Dec 14, 2026
Last update
May 7, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 7, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT07184632
Lead sponsor
Novo Nordisk A/S
Responsible party
Sponsor
First posted
Sep 22, 2025
Start date
Oct 1, 2025
Primary completion
Dec 14, 2026 (estimated)
Completion
Dec 14, 2026 (estimated)
Last update
May 7, 2026

Study contacts

Clinical Transparency (dept. 2834)
study director · Novo Nordisk A/S

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: NNC0662-0419

Start the discussion